Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) Return on Sales (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Return on Sales for 7 consecutive years, with 34.14% as the latest value for Q4 2025.

  • Quarterly Return on Sales fell 2321.0% to 34.14% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 8.92% through Dec 2025, down 336.0% year-over-year, with the annual reading at 8.92% for FY2025, 336.0% down from the prior year.
  • Return on Sales for Q4 2025 was 34.14% at Kymera Therapeutics, down from 33.51% in the prior quarter.
  • The five-year high for Return on Sales was 0.4% in Q4 2023, with the low at 34.14% in Q4 2025.
  • Average Return on Sales over 5 years is 7.82%, with a median of 3.7% recorded in 2022.
  • The sharpest move saw Return on Sales surged 299bps in 2021, then crashed -2321bps in 2025.
  • Over 5 years, Return on Sales stood at 2.23% in 2021, then fell by -8bps to 2.4% in 2022, then surged by 83bps to 0.4% in 2023, then tumbled by -2603bps to 10.93% in 2024, then crashed by -212bps to 34.14% in 2025.
  • According to Business Quant data, Return on Sales over the past three periods came in at 34.14%, 33.51%, and 7.38% for Q4 2025, Q3 2025, and Q2 2025 respectively.